168 related articles for article (PubMed ID: 35931003)
1. Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection.
Veschetti L; Boaretti M; Saitta GM; Passarelli Mantovani R; Lleò MM; Sandri A; Malerba G
Microbiol Res; 2022 Oct; 263():127140. PubMed ID: 35931003
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and variability of siderophore production in the
Sorlin P; Brivet E; Jean-Pierre V; Aujoulat F; Besse A; Dupont C; Chiron R; Jumas-Bilak E; Menetrey Q; Marchandin H
Microbiol Spectr; 2024 Mar; 12(3):e0295323. PubMed ID: 38315029
[No Abstract] [Full Text] [Related]
3. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.
Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H
Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850
[No Abstract] [Full Text] [Related]
4.
Gabrielaite M; Nielsen FC; Johansen HK; Marvig RL
Microb Genom; 2021 Jul; 7(7):. PubMed ID: 34232117
[No Abstract] [Full Text] [Related]
5. Exoproducts of the Most Common
Sahl C; Baumgarten M; Shannon O; Påhlman LI
Microbiol Spectr; 2023 Aug; 11(4):e0019523. PubMed ID: 37284754
[No Abstract] [Full Text] [Related]
6.
Menetrey Q; Sorlin P; Jumas-Bilak E; Chiron R; Dupont C; Marchandin H
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919046
[TBL] [Abstract][Full Text] [Related]
7. Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.
Amoureux L; Bador J; Bounoua Zouak F; Chapuis A; de Curraize C; Neuwirth C
J Cyst Fibros; 2016 Jul; 15(4):486-94. PubMed ID: 26778615
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the
Le Goff M; Vastel M; Lebrun R; Mansuelle P; Diarra A; Grandjean T; Triponney P; Imbert G; Gosset P; Dessein R; Garnier F; Durand E
Front Cell Infect Microbiol; 2022; 12():859181. PubMed ID: 35782124
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of
Billiot CE; Novak L; McDaniel MS; Lindgren NR; Swords WE
Infect Immun; 2023 Dec; 91(12):e0041623. PubMed ID: 37909751
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of
Veschetti L; Sandri A; Patuzzo C; Melotti P; Malerba G; Lleo MM
Microb Genom; 2021 Jul; 7(7):. PubMed ID: 34292148
[No Abstract] [Full Text] [Related]
11. Duplex real-time PCR assay for the simultaneous detection of
Price EP; Soler Arango V; Kidd TJ; Fraser TA; Nguyen TK; Bell SC; Sarovich DS
Microb Genom; 2020 Jul; 6(7):. PubMed ID: 32667877
[TBL] [Abstract][Full Text] [Related]
12. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis.
Recio R; Brañas P; Martínez MT; Chaves F; Orellana MA
J Med Microbiol; 2018 Jul; 67(7):952-956. PubMed ID: 29787364
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hypermutator isolates of Achromobacter spp. from cystic fibrosis patients.
Ridderberg W; Jensen Handberg K; Nørskov-Lauritsen N
Int J Med Microbiol; 2020 Feb; 310(2):151393. PubMed ID: 31969255
[TBL] [Abstract][Full Text] [Related]
14. Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.
Traglia G; Papalia M; Almuzara M; Gutkind G; Centrón D; Vay C; Radice M; Ramírez MS
Curr Microbiol; 2014 Oct; 69(4):501-6. PubMed ID: 24894902
[TBL] [Abstract][Full Text] [Related]
15. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.
Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M
Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836
[TBL] [Abstract][Full Text] [Related]
16. Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.
Filipic B; Malesevic M; Vasiljevic Z; Lukic J; Novovic K; Kojic M; Jovcic B
Front Cell Infect Microbiol; 2017; 7():224. PubMed ID: 28611955
[No Abstract] [Full Text] [Related]
17. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.
Raso T; Bianco O; Grosso B; Zucca M; Savoia D
APMIS; 2008 Sep; 116(9):837-41. PubMed ID: 19024606
[TBL] [Abstract][Full Text] [Related]
18. The
Pickrum AM; Riegert MO; Wells C; Brockman K; Frank DW
Microbiol Spectr; 2022 Aug; 10(4):e0208322. PubMed ID: 35856670
[TBL] [Abstract][Full Text] [Related]
19. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.
Talbot NP; Flight WG
Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622
[TBL] [Abstract][Full Text] [Related]
20. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
Lobo LJ; Tulu Z; Aris RM; Noone PG
Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
